metformin has been researched along with Benign Monoclonal Gammopathies in 4 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We defined metformin users as patients with diabetes who were given metformin consistently for 4 years after their diabetes diagnosis and before multiple myeloma development, death, or censorship." | 7.81 | Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study. ( Carlsson, NP; Carson, KR; Chang, SH; Colditz, GA; Luo, S; O'Brian, KK; Thomas, TS, 2015) |
| "Metformin has begun to be discussed as a potentially useful agent on the basis of the results of epidemiological and preclinical research showing that it may be beneficial in patients with leukaemia, lymphomas and multiple myeloma." | 5.72 | Reduced Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma in Type 2 Diabetes Mellitus: Will Metformin Never Stop Its Pleasant Surprises? ( Papachristou, S; Papanas, N; Popovic, DS, 2022) |
| " We defined metformin users as patients with diabetes who were given metformin consistently for 4 years after their diabetes diagnosis and before multiple myeloma development, death, or censorship." | 3.81 | Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study. ( Carlsson, NP; Carson, KR; Chang, SH; Colditz, GA; Luo, S; O'Brian, KK; Thomas, TS, 2015) |
| "Metformin has begun to be discussed as a potentially useful agent on the basis of the results of epidemiological and preclinical research showing that it may be beneficial in patients with leukaemia, lymphomas and multiple myeloma." | 1.72 | Reduced Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma in Type 2 Diabetes Mellitus: Will Metformin Never Stop Its Pleasant Surprises? ( Papachristou, S; Papanas, N; Popovic, DS, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Papachristou, S | 1 |
| Popovic, DS | 1 |
| Papanas, N | 1 |
| Chang, SH | 1 |
| Luo, S | 1 |
| O'Brian, KK | 1 |
| Thomas, TS | 1 |
| Colditz, GA | 1 |
| Carlsson, NP | 1 |
| Carson, KR | 1 |
| Boursi, B | 2 |
| Weiss, BM | 2 |
| Haynes, K | 1 |
| Mamtani, R | 2 |
| Yang, YX | 2 |
4 other studies available for metformin and Benign Monoclonal Gammopathies
| Article | Year |
|---|---|
Reduced Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma in Type 2 Diabetes Mellitus: Will Metformin Never Stop Its Pleasant Surprises?
Topics: Diabetes Mellitus, Type 2; Disease Progression; Humans; Metformin; Monoclonal Gammopathy of Undeterm | 2022 |
Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study.
Topics: Aged; Diabetes Mellitus; Female; Humans; Male; Metformin; Middle Aged; Monoclonal Gammopathy of Unde | 2015 |
Reappraisal of risk factors for monoclonal gammopathy of undetermined significance.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Diabetes Mellitus; Female; Humans; Hypoglycemic Agent | 2016 |
Impact of metformin on the progression of MGUS to multiple myeloma.
Topics: Antineoplastic Agents; Case-Control Studies; Disease Progression; Humans; Incidence; Metformin; Mono | 2017 |